US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant

Lilly And AstraZeneca Antibodies Retain Potency

 
• By Andrew McConaghie
  
Vir Biotechnology offices San Francisco
The US government has bought around $1.9bn worth of Xevudy so far, but further sales are in jeopardy following the results in BA.2. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip